End-stage renal disease. Mild or moderate hepatic impairment. High risk for hypersensitivity reactions in patients w/ HLA-B*5701 allele positive test result. Do not initiate therapy to patients who had been suspected of previous hypersensitivity on a abacavir-containing regimen. Do not re-initiate therapy after discontinuation of abacavir or abacavir-containing regimen. Do not re-initiate therapy after discontinuation of abacavir or abacavir-containing drugs' therapy. Lactic acidosis in association w/ hepatomegaly & hepatic steatosis. Patients w/ hepatomegaly, hepatitis or other known risk factors for liver disease & hepatic steatosis; infected w/ hepatitis C & treated w/ α interferon & ribavirin; discontinue in symptomatic setting of hyperlactatemia & metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels. Mitochondrial dysfunction in HIV-negative infants exposed in utero
& post-natally to nucleoside analogues. Lipodystrophy. Pancreatitis. Concomitant use w/ tenofovir disoproxil fumarate & lamivudine; ribavirin. Preexisting liver dysfunction including chronic active hepatitis; patients w/ significant underlying liver disorders. Chronic hepatitis B or C & treated w/ combination antiretroviral therapy. Immune reactivation syndrome. Osteonecrosis in patients w/ advanced HIV disease &/or long-term exposure to combination antiretroviral therapy. Opportunistic infections may still develop. MI. Pregnancy & lactation. Childn <3 mth.